

October 7, 2021



AlzeCure Pharma

- Introduction & Update

Martin Jönsson - CEO

Agenda

- Who we are
- Focus areas
- Pipeline & the science
 - Progress & goals in 2021



AlzeCure Pharma

- Working in **Alzheimer's Disease (AD)** and **Pain** – multi-billion markets / great unmet medical need
- Founded in **2016**, out of a research foundation sponsored by Alzheimerfonden
- **Experienced team** with extensive background within Pharma industry
- Based at Novum Science Park, **Karolinska Institute**, Stockholm, Sweden
- Three project platforms with multiple **small molecule** candidates
 - **NeuroRestore®** - A novel first-in-class symptomatic treatment for cognitive disorders, e.g. AD
 - **Alzstatin®** – An innovative disease-modifying treatment for AD
 - **Painless** – Innovative projects for osteoarthritic and neuropathic pain
- Listed on **Nasdaq First North Premier** Growth Market since Nov. 2018 (Ticker: ALZCUR)
- Market cap: **SEK 302m** (October 5, 2021)
- Cash position: **SEK 78m** (Q2 2021 report)



Our Business Model

- We are a **Research & Development** company
- Research & **develop through early clinical phase** and then **to out-license** or partner on our projects
- Gain incomes through:
 - **Upfront payments**
 - **Milestone payments**
 - **Royalties** on sold products



Small molecule drugs – AlzeCure's approach for increased success

DIFFERENCES BETWEEN SMALL MOLECULES & BIOLOGICS*

**SMALL MOLECULE
DRUG**

LARGE BIOLOGIC

AlzeCure focus



Small molecule drug



Monoclonal antibody
c. 25,000 atoms

**Smaller molecules can have increased likelihood of
penetrating the Blood Brain Barrier**

A pipeline of small-molecule programs

– Multiple candidates increase chance of success

Platform	Candidate	Indication	Research phase	Preclinical phase	Phase I	Phase II	Phase III
NeuroRestore®	ACD856	Alzheimer's Disease, Sleep disorders, Traumatic brain injuries Parkinson's disease				Ongoing Fully funded Ph I study	
	ACD857	Alzheimer's Disease					
Alzstatin®	ACD679	Alzheimer's Disease					
	ACD680	Alzheimer's Disease					
PainLess	ACD440	Neuropathic Pain				Finalized & positive read-out Preparing for phase II filing	
	TrkA-NAM	Osteoarthritic Pain & other severe pain conditions					

Phase completed

Phase ongoing




Our primary Focus area

Alzheimer's Disease

- Costs the society more than **oncology and cardiovascular diseases** TOGETHER
- The **patient population and costs** will TRIPLE in the next 30 years



Tripling patient population – due to the aging population



- **50 million** people worldwide live with dementia ...
- ... and **doubling every 20 years**
- Alzheimer's accounts for 60 - 70% of all dementia cases

Alzheimer's Disease - Progressive & lethal disorder with lack of available therapies

Pre-symptomatic Alzheimer's
10 - 20 years prior to symptoms

Symptomatic Alzheimer's
7 - 10 years life expectancy



- In Pre-symptomatic Alzheimer's, **A β amyloid pathology & plack** is building up in the brain but there are no clinical symptoms
- There are no preventive treatments for this stage of Alzheimer's

- The stage includes **dying neurons in the brain** which leads to **speech problems, memory loss and dementia**, and symptoms start manifesting



Sales: > US\$ 2bn/year

No drugs available

Very few drugs available - *associated with low efficacy and severe side effects*

HUGE UNMET MEDICAL NEED IN BOTH CATEGORIES





Enormous market potential

US sales

\$17 billion



Aduhelm® projected annual sales **if only 5% of the Alzheimer's patients are treated** with the product.*


=> 2nd biggest selling product in the US.

*) Nature, June 8, 2021; Landmark Alzheimer's drug Approval..."

Progression of Alzheimer's Disease



Healthy Brain



Mild Alzheimer's Disease*


AlzeCure work to preserve the healthy brain

*) Indication of Aduhelm® (aducanumab)

Two Alzheimer's platforms - 1st-in-class properties & potential game-changers

TARGET TWO KEY AREAS WITH A HIGH UNMET MEDICAL NEED

Disease-modifying therapy




Alzstatin[®]

Targeting Amyloid Production

- Novel Oral Small Molecule

Symptomatic therapy



NeuroRestore[®]


Improving Neuronal Function

- Novel Oral Small Molecule

NeuroRestore®

- A cognitive enhancer


NeuroRestore® enhances neuronal function & cognitive capabilities




- AlzeCure's compounds act as **enhancers of neurotrophin, e.g. BDNF/NGF signalling**, and the broad effect profile in this specific biological pathway **implies multiple possible indications**, including Alzheimer's disease, but also e.g. Parkinson's disease, Traumatic Brain injury and Sleep disorders.

Alzheimer's Disease Modifier – Preventing or delay disease progression

ALZHEIMER'S DISEASE PROGRESSION




Ab-42 - main culprit in Alzheimer progression





found a way to limit Ab-42 clustering

Alzstatin modulates the enzyme and thereby limits the clustering effect



The Amyloid cascade - Generating toxic and damaging fragments, including plaques, damaging neurons and brain structures

AlzeCure's GSM*
Alzstatin® reducing
Ab-42 to diminishing
the build-up of toxic
fragments and plaque



Our second Focus area

Chronic Pain

- Suicide due to chronic pain is as common as due to depression
- Most common cause for sick leaves, creating misery & high societal costs
- Opioid crisis in the US - is huge & reversing the mean average lifespan of Americans



Huge need for more efficacious and safer treatments

Our platform PAINLESS – Targeting unmet medical needs within pain



Neuropathic pain*

25 – 30 million patients

Project: ACD440



Osteoarthritis & severe pain conditions

> 300 million patients

Project: TrkA-NAM

TrkA-NAM – none-opioid treatment of severe pain conditions

Attractive Target population

E.g. **osteoarthritis** in patients who have experienced insufficient pain relief from 1st line standard of care or unacceptable side effects

Clinical validation

Mechanism with **strong validation** – step-changing clinical efficacy with novel anti-NGF mAbs - sets the standard for future therapies

Blockbuster opportunities

Blockbuster opportunities for NGF therapies that would avoid adverse events and allow non parenteral routes of administration



Differentiation factors for TrkA-NAM

- › **TrkA selective MoA** vs anti-NGF antibodies also targeting p75 signaling
 - › *Maintain **potent clinical efficacy***
 - › *Improved side-effect profile*
- › Convenient **oral administration** - small molecule compound
- › **No addiction** compared to opioids



Professor David Julius
Nobel prize medicine laureate 2021
University of California, San Francisco, USA



Prize motivation: ... for the discoveries of receptor (TRPV1) for temperature and touch.

The identification of and knowledge about the TRPV1 receptor is central for the mediation of neuropathic pain, which 7-8% of the adult population is affected by. AlzeCure Pharma is developing a TRPV1 antagonist (ACD440), which now is in clinical phase, for treatment of this pain condition.



ACD440 – Novel TRPV1 antagonist in clinical phase for neuropathic pain



PROJECT OVERVIEW

Emanates from Big Pharma

- › Approximately SEK 200m spent on project development
- › **Mode of action confirmed** in several Phase 1 clinical trials
- › Synthesized compound and formulation developed



VR1 – optimized for local delivery

- › The vanilloid receptor subtype 1 (TRPV1) is expressed in nociceptive sensory neurons
- › TRPV1 is upregulated in the skin of patients with neuropathic pain
- › **Strong scientific support** for peripheral/local treatment with TRPV1 antagonists

Phase 1b trial fully funded

- › The trial was fully funded with existing funds
- › **Trial** with topical formulation has now **ended**
- › Phase 1b study addressed **both tolerability & efficacy – POSITIVE OUTCOMES**

Now preparing **filling for a phase II clinical trial**

Neuropathic pain - Fast growing market

- The most valuable segment within the pain indications
- Poorly served patients
- Huge demand for better drugs

2020
\$11 billions

CARG to 2027
12.9% => **\$25 billions**

The Neuropathic Pain market was valued at \$10,8 billion in 2020 globally and is forecast to reach \$25,2 billions by 2027, at a Compound Annual Growth Rate (CARG) of 12,9%

Key short-term milestones for 2021

- ☒ **Read-out** of clinical 1b study **Painless ACD440** in summer 2021
- ☒ **Read-out** of clinical 1a SAD study **NeuroRestore[®] ACD856** summer 2021
- ☒ **Start NeuroRestore[®] ACD856** 1a MAD clinical study in second half 2021
- ☐ **Select CD** for our pain project **Painless TrkA-NAM** in second half 2021
- ☐ **File phase 2a** clinical study for **Painless ACD440** second half 2021

Key investment highlights in AlzeCure



Targeting areas of **huge unmet medical needs**



Strong team with extensive experience and track record



Platforms with first-in-class properties and potential **game-changers**




Parallel investments in several candidates and potent **follow-up programs**



Multi-billion dollar market **opportunities**



Evolving into a **phase II company**

The image is a composite. In the foreground, a pair of hands holds a realistic anatomical model of a human brain, split open to reveal internal structures like the ventricles and brainstem. The background is a blurred laboratory setting with various glassware and equipment. Overlaid on the left side is a semi-transparent, glowing blue image of a single neuron with its cell body and branching dendrites and axons.

Karolinska Institutet Novum Science Park
Hälsövägen 7, 141 57 Stockholm
SWEDEN

www.alzecurepharma.com

